Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future
- PMID: 35081285
- DOI: 10.1056/NEJMe2117663
Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future
Comment on
-
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous